Literature DB >> 10349897

Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina.

P A Heidenreich1, K M McDonald, T Hastie, B Fadel, V Hagan, B K Lee, M A Hlatky.   

Abstract

CONTEXT: Which drug is most effective as a first-line treatment for stable angina is not known.
OBJECTIVE: To compare the relative efficacy and tolerability of treatment with beta-blockers, calcium antagonists, and long-acting nitrates for patients who have stable angina. DATA SOURCES: We identified English-language studies published between 1966 and 1997 by searching the MEDLINE and EMBASE databases and reviewing the bibliographies of identified articles to locate additional relevant studies. STUDY SELECTION: Randomized or crossover studies comparing antianginal drugs from 2 or 3 different classes (beta-blockers, calcium antagonists, and long-acting nitrates) lasting at least 1 week were reviewed. Studies were selected if they reported at least 1 of the following outcomes: cardiac death, myocardial infarction, study withdrawal due to adverse events, angina frequency, nitroglycerin use, or exercise duration. Ninety (63%) of 143 identified studies met the inclusion criteria. DATA EXTRACTION: Two independent reviewers extracted data from selected articles, settling any differences by consensus. Outcome data were extracted a third time by 1 of the investigators. We combined results using odds ratios (ORs) for discrete data and mean differences for continuous data. Studies of calcium antagonists were grouped by duration and type of drug (nifedipine vs nonnifedipine). DATA SYNTHESIS: Rates of cardiac death and myocardial infarction were not significantly different for treatment with beta-blockers vs calcium antagonists (OR, 0.97; 95% confidence interval [CI], 0.67-1.38; P = .79). There were 0.31 (95% CI, 0.00-0.62; P = .05) fewer episodes of angina per week with beta-blockers than with calcium antagonists. beta-Blockers were discontinued because of adverse events less often than were calcium antagonists (OR, 0.72; 95% CI, 0.60-0.86; P<.001). The differences between beta-blockers and calcium antagonists were most striking for nifedipine (OR for adverse events with beta-blockers vs nifedipine, 0.60; 95% CI, 0.47-0.77). Too few trials compared nitrates with calcium antagonists or beta-blockers to draw firm conclusions about relative efficacy.
CONCLUSIONS: beta-Blockers provide similar clinical outcomes and are associated with fewer adverse events than calcium antagonists in randomized trials of patients who have stable angina.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349897     DOI: 10.1001/jama.281.20.1927

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  46 in total

1.  Coronary artery disease: part 2. Treatment.

Authors:  N Link; W Slater
Journal:  West J Med       Date:  2001-05

Review 2.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.

Authors:  Nadia Khan; Finlay A McAlister
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

4.  The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

Authors:  Jillian G Baker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

5.  Facts and principles learned at the 32nd annual Williamsburg Conference on Heart Disease.

Authors:  William Clifford Roberts; Hassan Farooq
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-04

Review 6.  Long term medical treatment of stable coronary disease.

Authors:  David M Shavelle
Journal:  Heart       Date:  2007-11       Impact factor: 5.994

Review 7.  Treatment of stable angina.

Authors:  Itsik Ben-Dor; Alexander Battler
Journal:  Heart       Date:  2007-07       Impact factor: 5.994

Review 8.  Sex-specific factors in microvascular angina.

Authors:  Tara Sedlak; Mona Izadnegahdar; Karin H Humphries; C Noel Bairey Merz
Journal:  Can J Cardiol       Date:  2014-02-27       Impact factor: 5.223

Review 9.  Medical management of stable coronary atherosclerosis.

Authors:  P Pellicori; P Costanzo; A C Joseph; A Hoye; S L Atkin; J G F Cleland
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

Review 10.  Anti-anginal and anti-ischemic effects of late sodium current inhibition.

Authors:  Neil J Wimmer; Peter H Stone
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.